



Antimicrobial Activity of Plant-Derived Products and Synthetic Derivatives

Guest Editors:

Prof. Dr. Constantinos Athanassopoulos

Department of Chemistry,
University of Patras, GR-26504
Rion, Patras, Greece

Prof. Dr. Carlos L. Cespedes Acuña

Basic Sciences Department,
Universidad del Bio Bio, Chillan,
Chile

Prof. Dr. María Cecilia Carpinella

Fine Chemicals and Natural
Products Laboratory, CIDIE
CONICET—Universidad Católica
de Córdoba, Córdoba, Argentina

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

The management of bacterial infections is a phenomenon with important implications for morbidity and mortality. Even though the number of drugs currently used in clinical practice of infectious diseases is high, the development of resistance necessitates the discovery of new effective agents. Natural products have been an endless source of compounds with great structural diversity, showing various modes of action against resistant microorganisms. These structures will enrich libraries to be used for the discovery of lead compounds and the development of drug candidates for successful therapies against resistant organisms.

This Issue intends to collect cutting-edge research and review works illustrating the potential of extracts and active principles obtained from plants, as well as derivatives therefrom against microorganisms, with special attention to those with resistant phenotypes, and it also aims to bring together pharmacognosists, computer-aided drug design scientists, and clinicians working as a multidisciplinary team in the area of natural products.

Keywords: plant extracts, plant-derived compounds, antibacterial activity, resistant strains





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi